News | February 09, 2015

Medtronic Introduces New Valve Sizes for CoreValve Evolut R System

Self-expanding TAVI valve gains CE Mark approval for 26, 29 mm versions

Corevalve, valve sizes

February 9, 2015 — Medtronic announced CE (Conformité Européene) mark for the 26 and 29 mm sizes of the CoreValve Evolut R System, a next-generation self-expanding valve for transcatheter aortic valve implantation (TAVI) providing the option to recapture and reposition the valve during procedures. The new larger valve sizes are delivered through a 14 French equivalent delivery system allowing small vessels to be accessed, and offer an extended sealing skirt intended to further promote valve sealing at the annulus.

The 23, 26 and 29 mm sizes of the CoreValve Evolut R and the CoreValve EnVeo R Delivery Catheter System are available in Europe and other countries that recognize the CE mark. It is not approved for commercial use in the United States, where it is currently undergoing clinical trials.

“The clinical experience with the Evolut R system has been exceptional. The system’s optimal positioning and delivery of the valve are essential to achieve the very best clinical results in TAVI. Evolut R’s low profile, positioning accuracy and enhanced sealing, all supported with the option to recapture and reposition during implantation, are a significant advance for transcatheter therapy,” said Ganesh Manoharan, M.D., consultant cardiologist, Royal Victoria Hospital, co-lead for the CoreValve Evolut R CE mark study slated for presentation at the 2015 American College of Cardiology (ACC) annual meeting. “Expanding the Evolut R valve size range enables physicians to bring these important advances to a much broader range of patients.”

The system is designed for first-time positioning accuracy and also offers an InLine Sheath that significantly reduces the profile to a 14 French equivalent, less than 1/5 inch; a smaller profile size provides a greater opportunity to treat patients with smaller vessels (down to 5 mm), which may minimize the risk of major vascular complications in some patients. The Evolut R valve is also anatomically designed for optimal fit and sealing, while maintaining strong hemodynamic performance.

For more information: www.medtronic.com


Related Content

News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
Subscribe Now